|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF623 |
Gene summary for ZNF623 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF623 | Gene ID | 9831 |
| Gene name | zinc finger protein 623 | |
| Gene Alias | ZNF623 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0A0MT18 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9831 | ZNF623 | LZE4T | Human | Esophagus | ESCC | 4.60e-03 | 1.29e-01 | 0.0811 |
| 9831 | ZNF623 | LZE20T | Human | Esophagus | ESCC | 3.79e-07 | 2.58e-01 | 0.0662 |
| 9831 | ZNF623 | LZE24T | Human | Esophagus | ESCC | 1.18e-06 | 2.45e-01 | 0.0596 |
| 9831 | ZNF623 | P2T-E | Human | Esophagus | ESCC | 3.97e-17 | 2.47e-01 | 0.1177 |
| 9831 | ZNF623 | P4T-E | Human | Esophagus | ESCC | 2.58e-08 | 2.14e-01 | 0.1323 |
| 9831 | ZNF623 | P5T-E | Human | Esophagus | ESCC | 2.82e-13 | 1.98e-01 | 0.1327 |
| 9831 | ZNF623 | P8T-E | Human | Esophagus | ESCC | 1.42e-24 | 1.39e-01 | 0.0889 |
| 9831 | ZNF623 | P9T-E | Human | Esophagus | ESCC | 3.73e-09 | 2.20e-01 | 0.1131 |
| 9831 | ZNF623 | P10T-E | Human | Esophagus | ESCC | 1.04e-14 | 2.44e-01 | 0.116 |
| 9831 | ZNF623 | P11T-E | Human | Esophagus | ESCC | 9.88e-07 | 2.75e-01 | 0.1426 |
| 9831 | ZNF623 | P12T-E | Human | Esophagus | ESCC | 1.79e-17 | 3.06e-01 | 0.1122 |
| 9831 | ZNF623 | P15T-E | Human | Esophagus | ESCC | 4.80e-15 | 3.18e-01 | 0.1149 |
| 9831 | ZNF623 | P16T-E | Human | Esophagus | ESCC | 3.07e-22 | 4.11e-01 | 0.1153 |
| 9831 | ZNF623 | P20T-E | Human | Esophagus | ESCC | 6.23e-04 | 1.38e-01 | 0.1124 |
| 9831 | ZNF623 | P21T-E | Human | Esophagus | ESCC | 8.66e-17 | 2.59e-01 | 0.1617 |
| 9831 | ZNF623 | P22T-E | Human | Esophagus | ESCC | 3.16e-18 | 2.54e-01 | 0.1236 |
| 9831 | ZNF623 | P23T-E | Human | Esophagus | ESCC | 1.82e-11 | 2.70e-01 | 0.108 |
| 9831 | ZNF623 | P24T-E | Human | Esophagus | ESCC | 8.02e-08 | 1.84e-01 | 0.1287 |
| 9831 | ZNF623 | P26T-E | Human | Esophagus | ESCC | 2.28e-13 | 2.48e-01 | 0.1276 |
| 9831 | ZNF623 | P27T-E | Human | Esophagus | ESCC | 3.45e-14 | 2.01e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF623 | SNV | Missense_Mutation | novel | c.1266N>T | p.Gln422His | p.Q422H | O75123 | protein_coding | deleterious(0.04) | possibly_damaging(0.888) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| ZNF623 | SNV | Missense_Mutation | novel | c.950G>A | p.Arg317Lys | p.R317K | O75123 | protein_coding | tolerated(1) | benign(0.365) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| ZNF623 | SNV | Missense_Mutation | c.910T>C | p.Ser304Pro | p.S304P | O75123 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-AR-A24N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF623 | SNV | Missense_Mutation | c.283N>G | p.Gln95Glu | p.Q95E | O75123 | protein_coding | tolerated(0.05) | benign(0.013) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZNF623 | SNV | Missense_Mutation | c.1130G>A | p.Cys377Tyr | p.C377Y | O75123 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1P7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
| ZNF623 | SNV | Missense_Mutation | novel | c.112N>T | p.Leu38Phe | p.L38F | O75123 | protein_coding | tolerated(0.09) | benign(0.044) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF623 | SNV | Missense_Mutation | rs373149668 | c.857C>T | p.Thr286Ile | p.T286I | O75123 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ZNF623 | SNV | Missense_Mutation | rs375460182 | c.398N>T | p.Thr133Met | p.T133M | O75123 | protein_coding | tolerated(0.09) | possibly_damaging(0.582) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ZNF623 | SNV | Missense_Mutation | rs370100274 | c.488N>A | p.Ser163Asn | p.S163N | O75123 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ZNF623 | SNV | Missense_Mutation | c.1175N>A | p.Arg392Gln | p.R392Q | O75123 | protein_coding | tolerated(0.64) | probably_damaging(0.999) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |